COR 10-Q Quarterly Reports

Cencora, Inc. reported solid financial results for the quarter ending December 31, 2025, demonstrating robust revenue growth driven by both its U.S. and International Healthcare Solutions segments. The company saw a significant increase in gross profit, largely attributed to the acquisition of RCA and favorable LIFO credit adjustments, while managing operating expenses effectively despite integration costs from recent acquisitions. Despite a notable increase in interest expense due to recent debt financings for acquisitions, Cencora maintained profitability, with net income attributable to Cencora, Inc. rising to $559.6 million. The company also provided strong forward-looking indications with the recent acquisition of OneOncology and an increased revolving credit facility, positioning it for continued growth and operational expansion. However, investors should remain aware of the ongoing opioid litigation accrual and other contingent liabilities, which represent a significant long-term financial commitment.

Cencora, Inc. (COR) reported strong revenue growth in its fiscal third quarter of 2025, with an 8.7% increase year-over-year, reaching $80.7 billion. This growth was driven by solid performance across both its U.S. and International Healthcare Solutions segments. Notably, the U.S. segment saw a significant contribution from increased sales of GLP-1 class drugs for diabetes and weight loss, which grew 18.6% in the quarter. Profitability also showed improvement, with gross profit rising 20.6% year-over-year, largely due to higher sales volumes and the positive impact of a LIFO credit this year compared to an expense last year. The acquisition of Retina Consultants of America (RCA) in January 2025 has begun to contribute positively to the U.S. segment's results. While operating expenses increased, primarily due to integration costs from RCA, overall segment operating income grew by 20.6%. The company also continues to manage its debt effectively, with significant credit facility capacity, and reiterated its commitment to shareholder returns through dividends and share repurchases.

Cencora, Inc. reported a strong first quarter for fiscal year 2025, demonstrating robust revenue growth driven by its U.S. Healthcare Solutions segment. Total revenue for the quarter increased by 10.3% year-over-year, reaching $75.5 billion, with the U.S. segment experiencing a significant 11.4% rise. This growth was bolstered by strong unit volume increases, notably a 36.1% surge in sales of GLP-1 class drugs for diabetes and weight loss, totaling $2.2 billion. Net income attributable to Cencora, Inc. rose to $717.9 million, a substantial increase from $420.8 million in the prior year's first quarter, translating to diluted earnings per share of $3.68. The company also benefited from a substantial gain related to antitrust litigation settlements, contributing significantly to the increase in gross profit. Despite increased operating expenses, largely due to the recent acquisition of Retina Consultants of America (RCA) and associated integration costs, the company managed to expand its operating income by 87.3% year-over-year to $1,036.2 million. Cencora also highlighted continued capital allocation through share repurchases and dividend payments.

Cencora, Inc. reported strong revenue growth in the fourth quarter of fiscal year 2024, with a 12.8% increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment. This growth was bolstered by significant sales of GLP-1 class products for diabetes and weight loss, as well as increased specialty product sales. Despite the revenue surge, net income attributable to Cencora, Inc. saw a decline to $488.6 million from $601.5 million in the prior year's comparable period, leading to a decrease in diluted earnings per share from $2.98 to $2.50. This profitability dip can be attributed to higher operating expenses, including increased litigation and opioid-related expenses, and a decrease in gains from antitrust litigation settlements. The company also completed a significant acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025, further impacting its financial position and future growth trajectory.

Cencora, Inc. reported robust revenue growth for the nine months ended June 30, 2024, driven by a significant increase in its U.S. Healthcare Solutions segment. This growth was fueled by higher unit volumes, particularly in GLP-1 class drugs for diabetes and weight loss, alongside increased sales of specialty products and COVID-19 vaccines. While gross profit saw a healthy increase, profit margins in the U.S. segment slightly contracted due to a higher mix of lower-margin GLP-1 products, though this was partially offset by higher-margin COVID-19 vaccine sales. The company's operating expenses also increased, impacted by higher distribution, selling, and administrative costs, as well as litigation and opioid-related expenses. Despite these pressures, overall segment operating income showed positive growth, particularly in the U.S. segment. Cencora also highlighted strong cash flow from operations, which was bolstered by effective working capital management, particularly an extended accounts payable cycle. The company continued its share repurchase program and maintained its quarterly dividend. Key financial considerations for investors include the ongoing strength in revenue, the impact of the GLP-1 drug trend on margins, and the significant ongoing liability related to opioid litigation, which continues to be managed with substantial reserves. The company's liquidity remains strong with significant availability under its credit facilities.

Cencora, Inc. (COR) reported a significant increase in revenue for both the three and six months ended March 31, 2024, driven primarily by strong performance in its U.S. Healthcare Solutions segment. This growth was fueled by higher unit volumes, increased sales of specialty products, and contributions from GLP-1 class drugs and COVID-19 vaccines. Despite increased operating expenses, particularly related to litigation and opioid expenses, the company demonstrated improved gross profit and operating income across its segments. Financially, the company shows robust revenue growth and managed its expenses effectively, leading to increased operating income. However, investors should note the substantial accrued litigation liability related to opioid settlements, which stands at $5.1 billion. While the company has a strong liquidity position with substantial cash and cash equivalents and access to credit facilities, the ongoing opioid litigation and the recent cybersecurity event present notable risks and require continued monitoring. The company also continues its share repurchase program and dividend payments, indicating a commitment to returning value to shareholders.

Cencora, Inc. (COR) reported strong revenue growth in the fourth quarter of fiscal year 2023, driven by a significant 15.9% increase in its U.S. Healthcare Solutions segment, bolstered by higher unit volumes, particularly in GLP-1 class drugs for diabetes and weight loss, specialty products, and COVID-19 vaccines. International Healthcare Solutions also saw a respectable 6.9% revenue increase, benefiting from growth in its European, Canadian, and Brazilian businesses, as well as the recent PharmaLex acquisition. Profitability saw a substantial improvement, with gross profit up 15.0% year-over-year, aided by increased sales and a favorable LIFO credit compared to an expense in the prior year. Operating income also saw a significant 30.0% increase, reflecting disciplined expense management and operating leverage from revenue growth. While the company continues to navigate significant opioid litigation accruals, a notable reduction in the opioid litigation settlement accrual due to a prepay significantly benefited current quarter results. The company also repurchased $385.5 million in common stock and increased its quarterly dividend, signaling confidence in its financial position and commitment to returning value to shareholders.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid revenue growth in its fiscal third quarter ended June 30, 2023, driven primarily by its U.S. Healthcare Solutions segment. Total revenue increased by 11.5% year-over-year, reaching $66.9 billion. This growth was propelled by increased unit volumes, particularly in diabetes and weight-loss medications (GLP-1 class) and specialty products, though partially offset by decreased sales of COVID-19 treatments. Net income attributable to AmerisourceBergen Corporation saw a significant increase, reaching $479.6 million for the quarter, a 18.1% rise from the prior year. Diluted earnings per share also improved to $2.35 from $1.92 in the same period last year. The company's strategic acquisitions, including PharmaLex and the investment in OneOncology, are expected to contribute to future growth. Despite ongoing legal matters, notably the opioid litigation settlement, Cencora's financial performance demonstrates resilience and operational strength.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong revenue growth in the first quarter of fiscal year 2023, driven primarily by its U.S. Healthcare Solutions segment. This segment saw a significant increase in revenue, largely attributed to unit volume growth and increased sales to major customers, despite a decline in COVID-19 treatment sales. The company's International Healthcare Solutions segment experienced a slight revenue decrease, impacted by a prior divestiture and unfavorable foreign currency exchange rates, though partially offset by contributions from recent acquisitions and ongoing business. While gross profit saw a modest increase, total operating expenses rose due to higher administrative, restructuring, and amortization costs. The company also completed a significant acquisition of PharmaLex, enhancing its global services capabilities, and announced a forthcoming investment in OneOncology. The ongoing opioid litigation remains a significant financial and operational consideration, with a substantial liability accrued.

Cencora, Inc. (COR), formerly AmerisourceBergen, reported solid revenue growth for the quarter ended December 31, 2022, with a 5.4% increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment. This growth was fueled by increased unit volumes and expanded sales to specialty physician practices, though partially offset by declining sales of COVID-19 treatments. The company also demonstrated improved gross profit, up 4.2%, benefiting from higher gross profit in its U.S. operations and a one-time gain from antitrust litigation settlements. While operating expenses rose due to increased distribution, selling, and administrative costs, the company managed to control litigation and opioid-related expenses. Despite a slight decrease in total segment operating income, largely due to international currency headwinds, Cencora's financial performance indicates resilience and continued operational execution.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid revenue growth of 12.5% in the third quarter of fiscal year 2022, reaching $60.1 billion. This growth was primarily driven by the strategic acquisition of Alliance Healthcare in June 2021 and organic growth across both its U.S. and International Healthcare Solutions segments. Despite increased operating expenses, largely due to integration costs and a goodwill impairment, the company demonstrated robust segment operating income growth of 19.9%, indicating effective operational management post-acquisition. While the company continues to navigate significant legal liabilities, particularly related to opioid litigation, substantial progress has been made in resolving these matters with a comprehensive settlement agreement in place. Management anticipates continued revenue growth and maintains a strong liquidity position supported by operating cash flows and available credit facilities, allowing for ongoing investments in technology and capital expenditures, as well as continued shareholder returns through dividends and share repurchases.

Cencora, Inc. (COR) reported strong revenue growth for the period ending March 31, 2022, driven significantly by the acquisition of Alliance Healthcare and continued growth across its U.S. and International Healthcare Solutions segments. The company demonstrated a substantial increase in gross profit, also largely attributable to the Alliance Healthcare acquisition and higher fees from distributing government-owned COVID-19 treatments. While operating expenses rose, primarily due to integration costs associated with Alliance Healthcare, operating income saw a notable increase, reflecting the positive impact of the acquisition and organic growth within the U.S. segment. Investors should note the significant increase in debt and interest expense, largely tied to the Alliance Healthcare acquisition financing. The company continues to manage its liquidity effectively and maintains availability under its credit facilities. A key ongoing concern is the substantial accrued litigation liability related to opioid settlements, which is being paid out over 18 years, though the company has accrued its estimated liability. Despite these challenges, the company has made progress in resolving opioid-related claims across various states.

Cencora, Inc. (COR), formerly AmerisourceBergen, reported strong revenue growth of 13.5% to $59.6 billion for the quarter ended December 30, 2021, compared to the prior year. This growth was primarily driven by the significant contribution from the acquisition of Alliance Healthcare in June 2021, which substantially expanded the company's international presence. While the U.S. Healthcare Solutions segment saw a more modest 2.7% revenue increase, the International Healthcare Solutions segment experienced a remarkable 604.2% surge, largely due to the Alliance Healthcare acquisition. The company also demonstrated robust growth in gross profit, which increased by 41.9% to $2.06 billion, benefiting from both the Alliance Healthcare acquisition and organic growth within its segments. Operating income saw a healthy increase of 17.8% to $644.4 million. Investors should note the significant increase in operating expenses, up 56.5%, largely attributable to the integration of Alliance Healthcare, and a substantial increase in interest expense due to debt financing for the acquisition. The company continues to manage significant litigation related to opioid settlements, with a $6.7 billion accrual in place.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong revenue growth for the third quarter and first nine months of fiscal year 2021, primarily driven by the significant acquisition of Alliance Healthcare and continued expansion in its Pharmaceutical Distribution Services segment. Revenue increased by 17.7% and 10.3% for the three and nine months ended June 30, 2021, respectively, compared to the prior year periods. This growth was bolstered by increased sales of specialty products, including COVID-19 treatments, and overall market expansion. The company also saw a substantial increase in gross profit, up 54.0% and 26.8% for the respective periods, benefiting from higher gross profit in its core segments, LIFO credits, and gains from antitrust litigation settlements. However, operating expenses also rose significantly (54.4% and 7.5%) due to the Alliance Healthcare acquisition, increased legal accruals for the proposed opioid settlement, and integration costs. Operationally, the company continues to navigate significant legal matters, notably the proposed comprehensive opioid settlement, which represents a substantial financial commitment. Despite these challenges, the company maintained solid cash flow from operations and a healthy liquidity position, with significant availability under its credit facilities, enabling it to manage its debt obligations and continue its share repurchase program and dividend payments.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid revenue growth in its first quarter of fiscal year 2021, with a 3.7% increase year-over-year to $49.2 billion. This growth was primarily driven by its Pharmaceutical Distribution Services segment, which saw higher sales of specialty products, including COVID-19 treatments. The company also experienced a significant improvement in operating income, which more than doubled to $624.3 million, benefiting from increased gross profit and reduced operating expenses compared to the prior year. A key development highlighted in the filing is the January 2021 agreement to acquire a majority of Walgreens Boots Alliance's (WBA) Alliance Healthcare businesses for approximately $6.5 billion. This strategic move is expected to expand Cencora's global reach and enhance its existing manufacturer services platform. The company also secured new debt financing and issued senior notes to fund this acquisition, signaling a proactive approach to growth and capital management.

Cencora, Inc. (COR), formerly AmerisourceBergen Corporation, reported a significant increase in revenue and operating income for the quarter ended December 31, 2020, compared to the prior year. Revenue grew by 9.7% to $52.5 billion, primarily driven by the Pharmaceutical Distribution Services segment, which saw higher sales of specialty products, including COVID-19 treatments, and organic growth from key customers. This top-line growth, coupled with improved gross profit margins and a favorable comparison to operating expenses (which were reduced by a prior year impairment charge), led to a substantial 107.7% increase in operating income to $547.2 million. Investors should note the company's ongoing significant opioid litigation, for which a substantial liability has been accrued, though the ultimate resolution and potential for further impact remain a key area of focus. Additionally, the company announced a major acquisition in January 2021 of a majority of Walgreens Boots Alliance's Alliance Healthcare businesses for approximately $6.5 billion, which is expected to significantly expand its international presence. While the company generated strong operating cash flow, it also has substantial debt obligations and commitments, including those related to the opioid litigation and the upcoming acquisition, necessitating careful management of its capital resources.

Cencora, Inc. (formerly AmerisourceBergen) reported its financial results for the period ending June 30, 2020. The company demonstrated resilience amidst the early stages of the COVID-19 pandemic, with revenue showing a slight increase year-over-year for both the quarter and the nine-month period. While gross profit saw a modest decrease due to factors like lower gains from antitrust litigation and LIFO expense, operating income remained relatively stable for the quarter and saw a slight increase for the nine months, aided by lower impairments and reduced depreciation and amortization. A significant factor impacting net income, particularly for the nine-month period, was a substantial discrete income tax benefit related to the exit from the PharMEDium business and the CARES Act. Liquidity remains strong, supported by operating cash flows and available credit facilities. The company continued its commitment to shareholder returns through dividend payments and share repurchases. Despite the ongoing challenges posed by the COVID-19 pandemic, including potential impacts on supply chains and customer financial health, Cencora is focused on business continuity and navigating the evolving economic landscape. The company's forward-looking statements indicate expectations for continued revenue growth, albeit at a moderated pace, and ongoing management of operational and legal risks, most notably the extensive opioid litigation.

Cencora, Inc. (COR) reported strong revenue growth of 9.5% year-over-year for the quarter ended March 31, 2020, reaching $47.4 billion. This increase was primarily driven by its Pharmaceutical Distribution Services segment, benefiting from growth in specialty product sales and an increase in demand related to the onset of COVID-19, which also boosted gross profit in the short term. Despite revenue growth, gross profit saw a slight decrease of 2.6% due to lower gains from antitrust litigation settlements and unfavorable LIFO (Last-In, First-Out) accounting adjustments. Operating income, however, significantly increased due to a substantial reduction in asset impairment charges related to the PharMEDium business compared to the prior year. A notable factor influencing net income was a significant tax benefit recognized in the current period, largely stemming from the company's decision to exit the PharMEDium business and provisions within the CARES Act.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported its third fiscal quarter results for the period ending December 30, 2019. The company saw a 5.4% increase in revenue year-over-year, driven primarily by its Pharmaceutical Distribution Services segment and growth in its 'Other' segments, which include MWI Animal Health and Global Commercialization Services. This revenue growth was partially offset by a significant decline in gross profit, largely due to lower gains from antitrust litigation settlements and a shift from a LIFO credit to LIFO expense. The company's operating income experienced a substantial decrease of 44.9%, significantly impacted by a $138 million impairment charge related to PharMEDium's long-lived assets. Additionally, net income attributable to AmerisourceBergen Corporation was considerably lower due to the impairment charge, a decrease in gross profit, and a one-time tax benefit recognized in the prior year. The company also announced its decision to exit the PharMEDium compounding business in early 2020, anticipating further impairments and exit costs, but also a significant tax benefit.

Cencora, Inc. (COR), formerly AmerisourceBergen, reported a 4.9% increase in revenue for the three months ended June 30, 2019, reaching $45.2 billion, and a 7.5% increase for the nine-month period to $133.9 billion, year-over-year. This growth was primarily driven by its Pharmaceutical Distribution Services segment. While gross profit saw a modest increase of 1.6% for the quarter, it experienced a more substantial 10.4% rise for the nine-month period, bolstered by antitrust litigation settlements and LIFO credits. A significant factor impacting profitability was a $570.0 million impairment of long-lived assets related to its PharMEDium compounding operations, which heavily influenced the operating income and net income figures for the nine-month period, leading to a 27.7% decrease in operating income compared to the prior year. Despite this, the company's liquidity remains strong, supported by significant cash flows from operations and substantial availability under its credit facilities.

Cencora, Inc. (COR) reported a significant decline in net income for the quarter ended March 31, 2019, primarily due to a substantial $570 million impairment charge related to long-lived assets at its PharMEDium subsidiary. While revenue increased by 5.6% year-over-year to $43.3 billion, driven by growth in the Pharmaceutical Distribution Services segment, the substantial impairment charge overshadowed this top-line growth. Despite the net income drop, the company's core distribution business demonstrated resilience. The report also highlights the ongoing complexities of legal matters, particularly opioid-related lawsuits, and the successful resolution of certain antitrust litigation, which provided a notable gain. Investors should monitor the ongoing resolution of the PharMEDium situation and potential future impacts of legal liabilities.

AmerisourceBergen Corporation (COR) reported solid revenue growth of 12.2% year-over-year for the quarter ended December 31, 2018, primarily driven by its Pharmaceutical Distribution Services segment. This growth was bolstered by contributions from recent acquisitions and consolidations, including H.D. Smith and Profarma. However, net income and earnings per share were significantly lower compared to the prior year period, largely due to a substantial one-time income tax benefit recognized in the previous year resulting from the Tax Cuts and Jobs Act of 2017. The company's operating expenses saw an increase, particularly in distribution, selling, and administrative costs, influenced by the integration of new acquisitions. Despite these increases, operating income grew by 14.0% year-over-year, supported by gains from antitrust litigation settlements and the reversal of a previously estimated opioid stewardship assessment. Management expects continued revenue growth in the mid-single digits for fiscal year 2019, but faces ongoing challenges including industry consolidation, regulatory changes, and legal matters, notably those related to opioid litigation and compounding facility compliance.

Cencora, Inc. (formerly AmerisourceBergen) reported a significant increase in revenue for the nine months ended June 30, 2018, driven by its Pharmaceutical Distribution Services segment, bolstered by the consolidation of Profarma and the acquisition of H.D. Smith. Despite revenue growth, operating expenses, particularly distribution, selling, and administrative costs, also rose due to integration and IT system implementation costs. Net income and earnings per share saw a substantial uplift, largely attributable to the positive impact of the Tax Cuts and Jobs Act of 2017 and a decrease in prior-year litigation settlement charges. The company's balance sheet shows a healthy increase in total assets, driven by acquisitions and consolidated entities, alongside a rise in both current and long-term liabilities, reflecting increased debt to fund these activities. Cash flow from operations improved significantly year-over-year, indicating better working capital management, although the company continues to rely on its credit facilities for seasonal working capital needs. Investors should monitor the ongoing litigation and opioid-related costs, as well as the integration of recent acquisitions and the impact of the new tax regime.

Cencora, Inc. (formerly AmerisourceBergen) reported solid revenue growth for the first six months of fiscal year 2018, with a 10.5% increase in the latest quarter and an 8.2% increase year-to-date. This growth was primarily driven by its Pharmaceutical Distribution Services segment, bolstered by strategic acquisitions such as H.D. Smith and the consolidation of Profarma in Brazil. While gross profit remained relatively flat year-over-year for the quarter, it saw a 3.2% increase for the six-month period. However, the company experienced a significant increase in operating expenses, largely due to integration costs from acquisitions, new IT system implementations, and a suspension of operations at its Memphis compounding facility. Net income for the quarter declined due to lower operating income and higher non-operating losses, partially offset by a lower tax rate. Conversely, net income for the six-month period was significantly higher, largely driven by the favorable impact of the Tax Cuts and Jobs Act of 2017. The company is navigating increased litigation expenses, particularly related to opioid lawsuits, which contributed to higher employee severance, litigation, and other costs. Despite these challenges, Cencora continues to execute its strategic initiatives, including acquisitions and debt management. The company's liquidity remains adequate, supported by operating cash flows and available credit facilities. Investors should monitor the ongoing opioid litigation, the recovery of operations at the Memphis facility, and the integration of recent acquisitions as key factors influencing future performance.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a strong quarter ending December 31, 2017, with significant revenue growth and a substantial boost in net income, largely driven by the positive impact of the Tax Cuts and Jobs Act of 2017. Revenue increased by 6.0% year-over-year, primarily fueled by the Pharmaceutical Distribution Services segment. Despite increased operating expenses related to infrastructure and IT system implementations, operating income saw a modest increase. The company also made strategic moves, including the acquisition of NEVSCO and the completion of the significant H.D. Smith acquisition shortly after the quarter's end, which is expected to enhance its scale and support for independent pharmacies. The company also strengthened its international presence by increasing its ownership in Profarma and its joint venture in Brazil, with plans to consolidate their results going forward. Investors should note the substantial net income increase, which is heavily influenced by a large discrete tax benefit related to the 2017 Tax Act, lowering the effective tax rate significantly. While the core business demonstrated solid revenue growth, the company also faced operational challenges, such as the temporary suspension of production at a 503B outsourcing facility, impacting its pharmaceutical compounding operations. Management anticipates continued revenue growth and expects the lower tax rate to positively impact future effective tax rates.

Cencora, Inc. (COR) reported a significant year-over-year decline in net income for the three months ended June 30, 2017, primarily due to a substantial increase in litigation settlement charges. Revenue showed modest growth of 4.9% for the quarter, driven by increased sales within its Pharmaceutical Distribution Services segment, particularly from larger customers and ABSG business units, though this was partially offset by a decline in sales of Hepatitis C products. The company's balance sheet reflects a strong increase in accounts receivable and merchandise inventories, alongside a significant decrease in cash and cash equivalents compared to the prior year-end. While the company maintains substantial liquidity through its revolving credit facilities, the operating cash flow for the first nine months of fiscal 2017 was notably lower than the previous year, impacted by changes in payment terms with a major customer and a significant litigation settlement payment expected before the fiscal year-end. Investors should closely monitor the resolution of ongoing legal matters and their potential impact on future financial performance.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported revenue of $37.15 billion for the third quarter ended March 31, 2017, a 4.1% increase compared to the prior year period. This growth was primarily driven by increased sales within the Pharmaceutical Distribution Services segment, particularly from larger customers and specialty oncology products. Despite the revenue increase, net income saw a notable decline, falling to $411.5 million from $603.5 million in the prior year quarter. This decrease was largely attributed to a significant year-over-year reduction in LIFO expense, which had inflated the prior year's profitability, and an absence of warrant income that benefited the prior year's results. The company's operational efficiency initiatives helped keep distribution, selling, and administrative expenses relatively flat as a percentage of revenue. Looking at the balance sheet, total assets grew to $34.4 billion, with current assets increasing due to higher merchandise inventories and accounts receivable. Total liabilities also rose, largely driven by substantial accounts payable. Stockholders' equity increased, reflecting retained earnings growth, though partially offset by share repurchases. The company continues to manage its debt effectively, with strong availability under its credit facilities. Investors should note the significant ongoing legal matters, particularly those related to controlled substances and government investigations, which represent a material uncertainty and potential financial risk.

Cencora, Inc. (COR) reported its financial results for the quarter ending December 31, 2016. The company demonstrated revenue growth of 4.0% year-over-year, reaching $38.17 billion, driven by increases in both its Pharmaceutical Distribution and Other segments. While revenue expanded, net income saw a decline from $329.6 million in the prior year to $247.2 million in the current quarter. This decrease was primarily influenced by a significant shift in income tax expenses, with a substantial benefit recorded in the prior year versus an expense in the current period, and the absence of a large warrant expense that impacted the prior year quarter. Despite the lower net income, the company maintained a strong operational performance with an increase in total segment operating income by 2.0%. The company also continued its commitment to shareholder returns through increased dividends and active share repurchases. Management highlighted initiatives to improve operating efficiency and expects continued revenue growth in fiscal year 2017. Investors should note the ongoing legal matters and investigations, which, while not currently quantifiable, represent a potential risk factor.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a strong financial performance for the nine months ended June 30, 2016, with significant revenue growth driven by its Pharmaceutical Distribution segment and contributions from recent acquisitions. Revenue increased by 8.8% year-over-year, reaching $109.3 billion, with notable growth in both the core distribution business and the 'Other' segment, which includes animal health and consulting services. The company demonstrated improved profitability, with gross profit increasing by 23.2% year-over-year, bolstered by a reduction in LIFO expense and substantial gains from antitrust litigation settlements. Despite a rise in distribution, selling, and administrative expenses, largely due to acquisitions, operating income saw a healthy increase, particularly in the 'Other' segment. A significant factor impacting profitability was the favorable tax adjustment related to warrants, which converted a substantial prior-year loss from operations into a significant profit for the nine-month period.

AmerisourceBergen Corporation (COR) reported a solid first quarter of fiscal year 2016, demonstrating strong revenue growth and a significant shift from net loss to net income. Total revenue increased by 9.3% year-over-year for both the three and six-month periods, driven by the Pharmaceutical Distribution segment and the "Other" segment, bolstered by recent acquisitions like MWI and PharMEDium. This top-line growth, combined with favorable changes in LIFO expense and a significant positive adjustment related to Warrants, propelled the company to a net income of $604.1 million for the quarter, a stark contrast to the net loss reported in the prior year. Investors will be interested in the company's continued strategic acquisitions, its robust revenue generation, and the positive impact of the Warrants adjustment on net income. While operational expenses, particularly distribution, selling, and administrative costs, increased due to acquisitions, the overall financial performance indicates a healthy recovery and growth trajectory. The company's liquidity remains strong, supported by significant credit facilities and operating cash flows, enabling continued investment in growth initiatives and shareholder returns.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong revenue growth for the quarter ended December 31, 2015, with a 9.3% increase year-over-year, driven by its Pharmaceutical Distribution segment and a significant contribution from its 'Other' segment, largely due to the acquisition of MWI Veterinary Supply. Despite increased operating expenses, including warrant expenses and acquisition-related costs, the company achieved a substantial net income driven by a significant income tax benefit related to a private letter ruling on the fair value of warrants issued to Walgreens Boots Alliance. The company also announced a substantial increase in its quarterly cash dividend and continued its share repurchase program. Management highlighted the acquisition of PharMEDium Healthcare Holdings for $2.7 billion as a key strategic move. While the company faces ongoing litigation risks and regulatory scrutiny, its liquidity position remains strong, supported by significant availability under its credit facilities.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported its financial results for the quarterly period ended June 30, 2015. The company demonstrated strong top-line growth, with revenue increasing by 12.8% for the quarter and 14.2% for the nine-month period compared to the prior year. This growth was primarily driven by increased sales to Walgreens Boots Alliance (WBA), the acquisition of MWI Veterinary Supply, and robust performance in its specialty distribution businesses. Despite the revenue growth, the company experienced a net loss of $499.2 million for the nine-month period, largely influenced by significant warrant expenses and LIFO (Last-In, First-Out) expense. The warrant expense, in particular, is highly sensitive to changes in the company's stock price. The company also highlighted its ongoing efforts to mitigate the potential dilutive effects of outstanding warrants through share repurchase programs and hedging strategies. Management expects continued revenue growth in fiscal year 2015, driven by ongoing WBA distribution and market trends.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a significant increase in revenue for the six months ended March 31, 2015, driven by higher sales to Walgreens Boots Alliance (WBA) and the recent acquisition of MWI Veterinary Supply. This revenue growth was partially offset by increased operating expenses, notably a substantial rise in warrant expense due to stock price appreciation and higher LIFO expenses. Despite revenue growth, the company experienced a net loss for both the three and six-month periods, primarily attributable to these significant expenses. The company's balance sheet shows a considerable increase in total assets, largely due to goodwill and intangible assets arising from the MWI acquisition. Debt levels also increased significantly, mainly from new borrowings to finance the acquisition. Management highlights strong operational cash flow generation, supported by an increase in accounts payable and accrued expenses, which helped fund working capital needs, capital expenditures, and financing activities, including share repurchases and dividends.

Cencora, Inc. (COR) reported a significant revenue increase of 15.1% year-over-year for the quarter ended December 31, 2014, reaching $33.6 billion. This growth was driven by increased sales across its Pharmaceutical Distribution segment, notably including a full quarter of generic drug distribution to Walgreens Boots Alliance (WBA) and strong performance in specialty drug distribution through ABSG. The "Other" segment also contributed positively. Despite robust revenue growth, the company reported a net loss of $199.9 million, or $0.91 per diluted share, primarily due to substantial warrant expenses and LIFO expense. Warrant expense, related to the strategic relationship with WBA, significantly impacted earnings. The company continues to manage its liquidity effectively, with substantial cash balances and available credit facilities, and has a substantial share repurchase program in place to mitigate potential dilution from warrants.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a challenging third quarter for fiscal year 2014, with a net loss of $12.8 million, or $0.06 per diluted share, compared to a net income of $168.4 million in the prior year quarter. This downturn was largely driven by a significant increase in warrant expense related to their strategic relationship with Walgreens and Alliance Boots, as well as higher LIFO expense and a loss on early debt retirement. Despite the quarterly loss, the nine-month period showed a net income of $208.7 million, though down from $382.7 million in the prior year. Revenue demonstrated strong growth, increasing by 38.5% year-over-year for the quarter to $30.3 billion, primarily due to the continued ramp-up of the distribution agreement with Walgreens. However, the pharmaceutical distribution segment's gross profit margin declined due to a higher mix of lower-margin brand business and competitive pressures. Investors should note the significant increase in debt, particularly the issuance of new senior notes, to facilitate debt retirement and general corporate purposes, including share repurchases. The company is actively managing the potential dilutive effects of warrants through hedging strategies and share repurchases. While the top-line revenue growth is positive, the impact of the warrant expense and margin pressures on profitability remains a key focus for investors in the near term. The company also faces ongoing legal proceedings and investigations, particularly concerning controlled substance diversion, which could have future financial implications.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported significant revenue growth in the first two quarters of fiscal year 2014, primarily driven by its expanded distribution contract with Walgreens. Total revenue increased by 38.6% year-over-year for both the three and six-month periods ending March 31, 2014. However, this revenue growth came with a notable decrease in profitability, with net income for the quarter falling to $180.1 million from $45.6 million in the prior year's comparable period, and for the six-month period, net income was $221.5 million compared to $214.2 million. Diluted earnings per share from continuing operations also saw a decline. The company's balance sheet reflects a substantial increase in both accounts receivable and merchandise inventories, likely due to the integration of the Walgreens business. Despite increased revenues, operating income experienced a decline of 14.0% for the quarter and 29.1% for the six-month period. This was influenced by increased operating expenses, particularly distribution, selling, and administrative costs, and a significant warrant expense related to the strategic partnership with Walgreens and Alliance Boots. Investors should closely monitor the impact of the Walgreens partnership on margins and the company's ability to manage inventory and receivables effectively.

AmerisourceBergen Corporation (COR) reported a significant increase in revenue for the quarter ended December 31, 2013, driven primarily by its Pharmaceutical Distribution segment, which saw a 39% uplift year-over-year. This growth is largely attributable to the new distribution contract with Walgreens, which significantly boosted sales for ABDC. Despite the revenue surge, net income and diluted earnings per share from continuing operations saw a substantial decrease compared to the prior year quarter. This decline is primarily due to a significant increase in operating expenses, notably the $116.3 million warrant expense related to agreements with Walgreens and Alliance Boots, and a higher effective income tax rate resulting from the non-deductible portion of this warrant expense. Despite the decrease in profitability, the company's liquidity remains strong, supported by substantial availability under its revolving credit facility and receivables securitization facility. Management anticipates continued revenue growth in fiscal year 2014, fueled by the ongoing integration of the Walgreens contract and potential benefits from the Affordable Care Act. Investors should note the substantial one-time warrant expense and the related impact on tax rates as key factors influencing the current quarter's profitability, while also recognizing the underlying operational growth driven by strategic partnerships.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a mixed financial performance for the quarter ended June 30, 2013. Revenue saw a significant increase of 13.3% year-over-year to $21.9 billion, driven by growth in both the Pharmaceutical Distribution and Other segments. This growth was bolstered by a new ten-year distribution agreement with Walgreens, expected to contribute substantially in fiscal 2014, and a large contract with Express Scripts. However, profitability was impacted by a substantial LIFO charge of $122.1 million in the quarter, leading to a 15.8% decrease in gross profit to $562.5 million. Operating income also fell significantly by 58.5% to $134.6 million. The company also reported significant warrant expense related to its strategic arrangements with Walgreens and Alliance Boots, impacting the effective tax rate. Discontinued operations, stemming from the divestiture of AndersonBrecon and AmerisourceBergen Canada Corporation, contributed a gain on sale in the current quarter. The company maintained a strong liquidity position with substantial availability under its credit facilities and reported a robust cash flow from operations, although working capital saw some pressure from increased inventory and receivables.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported its first quarter results for fiscal year 2013, showing a modest increase in revenue of 4.1% to $20.5 billion for the quarter and 4.8% to $41.6 billion for the first six months. This growth was driven by both the Pharmaceutical Distribution segment and the 'Other' segment, which includes World Courier acquired in April 2012. However, net income significantly decreased due to losses from discontinued operations, particularly related to the planned divestitures of AndersonBrecon and AmerisourceBergen Canada Corporation, which included substantial goodwill impairment and loss on sale charges. The company also announced a significant strategic partnership with Walgreen Co. and Alliance Boots GmbH, including a ten-year pharmaceutical distribution agreement and the issuance of warrants to Walgreens and Alliance Boots for a minority equity stake in Cencora. While this partnership is expected to drive future revenue growth, particularly starting in fiscal year 2014 with the integration of Walgreens' generic drug distribution, it also introduces potential dilution and operational complexities. The company's balance sheet remains strong with significant cash on hand and available credit facilities, though increased inventory and accounts receivable were noted for the period.

AmerisourceBergen Corporation (COR) reported solid revenue growth for the quarter ended December 31, 2012, driven by its Pharmaceutical Distribution segment and significant contributions from its 'Other' segment, bolstered by recent acquisitions. While overall revenue increased by 5.7% year-over-year to $21.5 billion, the company's gross profit saw a notable increase of 15.1%, partly due to a $12.3 million gain from antitrust litigation settlements. However, operating expenses also rose significantly by 27.2%, largely attributable to the integration costs of acquisitions, impacting the Pharmaceutical Distribution segment's operating income which saw a slight decrease. The company demonstrated a strong commitment to shareholder returns, increasing its quarterly cash dividend by 62% and actively repurchasing shares, spending $96.9 million to complete its previously announced $750 million share repurchase program and initiating a new $750 million program with $187.6 million spent in the quarter. Despite a substantial decrease in cash from operations compared to the prior year, primarily due to increased working capital needs associated with a new large customer contract, the company maintains adequate liquidity through its revolving credit facility and securitization facility.

Cencora, Inc. (COR), formerly AmerisourceBergen Corporation, reported its financial results for the quarterly period ended June 30, 2012. The company experienced a slight decrease in overall revenue year-over-year, primarily driven by a decline in its Pharmaceutical Distribution segment, particularly from its AmerisourceBergen Drug Corporation (ABDC) unit. This was partially offset by strong growth in the 'Other' segment, largely attributable to recent acquisitions. Net income saw a modest decrease, though diluted earnings per share showed an increase due to a reduction in outstanding shares. The company also highlighted significant debt financing activities and ongoing share repurchase programs.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid financial performance for the quarter ended March 31, 2012. Revenue saw a modest increase, driven by growth in the Specialty Group (ABSG) and contributions from recent acquisitions, though this was partially offset by a decline in the generic drug market and the loss of a major retail customer. The company demonstrated strong operational efficiency, with operating income increasing slightly year-over-year. Despite increased interest expenses due to new debt issuance, net income remained stable, and diluted Earnings Per Share (EPS) saw a healthy increase, reflecting effective share repurchases. Cencora's liquidity position remains robust, supported by significant cash reserves and ample availability under its credit facilities, positioning the company to manage its working capital needs and pursue strategic growth initiatives, including its recently announced acquisition of World Courier Group.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported solid revenue growth in the quarter ended December 31, 2011, driven by its Pharmaceutical Distribution segment. The company acquired TheraCom, LLC for $250 million, expanding its consulting services, which is expected to contribute positively to future revenue. Despite a slight increase in interest expenses due to new debt issuance, the company demonstrated improved operating income and net income compared to the prior year period. The company also actively managed its capital structure, issuing new senior notes and continuing its share repurchase program, signaling confidence in its financial health and commitment to shareholder returns. Financially, AmerisourceBergen maintained a strong liquidity position with substantial cash and cash equivalents and significant availability under its revolving credit facilities and receivables securitization program. While facing some headwinds such as the loss of a major retail customer and potential impacts from generic drug conversions and changes in reimbursement rates, the company's diversified business model and strategic acquisitions position it for continued operational performance. Investors should monitor the integration of TheraCom and the impact of upcoming generic drug launches on gross profit margins.

Cencora, Inc. (COR) reported a solid quarter ending June 30, 2011, with revenue increasing by 2.9% year-over-year to $20.2 billion. This growth was primarily driven by the AmerisourceBergen Drug Corporation (ABDC) segment, which saw a 4% revenue increase, partly offset by a 2% decline in the AmerisourceBergen Specialty Group (ABSG) segment. The company demonstrated improved profitability, with gross profit rising 11.1% and operating income growing 12.5%. This was attributed to the successful launch of specialty generic oncology drugs, strong performance in non-specialty generic programs, and increased contributions from fee-for-service agreements with manufacturers. Despite increased operating expenses related to IT system upgrades and other initiatives, Cencora managed to improve its operating margin by 13 basis points. Net income increased by 13.0%, leading to a 15.8% rise in diluted earnings per share to $0.66.

Cencora, Inc. (COR) reported solid financial performance for the quarter and six months ended March 31, 2011. Revenue saw modest growth driven by the AmerisourceBergen Drug Corporation (ABDC) segment, despite a decline in the AmerisourceBergen Specialty Group (ABSG) due to the discontinuation of a contract. Notably, gross profit and operating income showed significant increases, outperforming revenue growth, largely attributed to the successful launch and profitability of specialty generic products, particularly in oncology. The company is actively managing its capital resources, demonstrating strong cash flow from operations and maintaining substantial availability under its credit facilities. Cencora is also returning value to shareholders through share repurchases and consistent dividend payments. While facing some headwinds, such as the upcoming loss of a large retail customer and the ongoing investment in its ERP system implementation, the company projects continued revenue growth and expresses confidence in its liquidity and ability to meet its financial obligations.

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a solid financial performance for the quarter ending December 31, 2010. Revenue saw a modest increase of 2.9% year-over-year, reaching $19.9 billion, driven primarily by growth in its AmerisourceBergen Drug Corporation (ABDC) segment, which offset a decline in the AmerisourceBergen Specialty Group (ABSG). Net income grew by 6% to $160.5 million, and diluted earnings per share increased by 10% to $0.57, indicating effective cost management and strong operational leverage. Investors should note the company's continued focus on returning capital to shareholders, with increased quarterly dividends and significant share repurchases. Management anticipates continued revenue growth in the low single digits for fiscal year 2011, supported by market trends and new product introductions. However, potential headwinds include the increasing use of generics, industry competition, and ongoing legal matters, particularly the significant 'Qui Tam' litigation, which remains a key area of concern for potential financial and reputational impact.

AmerisourceBergen Corporation (COR) reported a solid financial performance for the quarter ended June 30, 2010, demonstrating growth in revenue and operating income compared to the prior year. Revenue increased by 6.6% to $19.6 billion, driven by strong performance in its Pharmaceutical Distribution segment, particularly within AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The company also saw a significant improvement in gross profit margin, up 18 basis points to 3.00%, largely attributed to the robust performance of its generic programs and a notable benefit from a new generic oncology drug launch. This growth, coupled with operating expense leverage, led to a 32.3% increase in operating income for the quarter. From a balance sheet perspective, the company maintained a strong liquidity position with substantial cash and cash equivalents, while also actively managing its debt structure. AmerisourceBergen continued its commitment to shareholder returns through share repurchases and dividend increases. Despite the positive financial trends, investors should remain aware of ongoing legal proceedings and potential risks outlined in the filing, which could impact future results.

AmerisourceBergen Corporation (now Cencora, Inc.) reported strong revenue growth of 11.5% for the quarter ended March 31, 2010, reaching $19.3 billion. This growth was primarily driven by its Pharmaceutical Distribution segment, with notable contributions from AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The company also saw a significant increase in operating income, up 25.4% year-over-year, driven by gross profit improvements stemming from generic product introductions and enhanced generic program profitability. Diluted earnings per share from continuing operations also saw a substantial rise. The company maintained a strong liquidity position with ample availability under its credit facilities and robust operating cash flow. Despite the positive operational results, investors should note the ongoing legal proceedings, including a qui tam matter and related shareholder derivative action, which could present future uncertainties. The company also continues to manage its debt structure, recently issuing new senior notes and repaying a portion of its revolving credit facility, aiming to extend debt maturities and improve financial flexibility. Management is optimistic about continued revenue growth in fiscal year 2010, projecting a range of 7% to 8%, though it anticipates a moderation in the second half of the year.

AmerisourceBergen Corporation (now Cencora, Inc.) reported strong financial results for the quarter ended December 31, 2009. Revenue increased by a significant 12% year-over-year, driven by robust growth in both its institutional and retail customer segments, notably from new large customer acquisitions. The company's gross profit saw an impressive 15% increase, largely attributable to successful generic product launches and the continued strong performance of its generic programs. This, combined with improved operating leverage and a reduced operating expense ratio, led to a substantial 33% increase in operating income. Despite increased interest expenses due to new debt issuances, net income from continuing operations grew by 34%, translating to a 44% increase in diluted earnings per share. The company also demonstrated a commitment to returning capital to shareholders through increased dividends and active share repurchase programs. Management raised its fiscal year 2010 revenue growth forecast, signaling confidence in sustained performance amidst favorable industry trends, although potential headwinds from competition and evolving regulatory landscapes were acknowledged.

Cencora, Inc. (COR) reported its second quarter fiscal year 2009 results, demonstrating resilience and growth in a challenging economic environment. Total revenue saw a modest 2% increase year-over-year, driven by new customer acquisitions and strong performance in its specialty group (ABSG), which more than offset the loss of a significant retail customer. Despite this revenue growth, the company faced headwinds from declining anemia drug sales and the anniversary impact of losing a large retail customer. Gross profit margins improved due to stronger generic programs and fee-for-service agreements, while operating income also saw a healthy increase, reflecting effective cost management and operational efficiencies. The company continued its strategic capital allocation, including share repurchases and dividend payments, supported by robust liquidity and access to credit facilities.